Merck & Co INC (MRK) Shares Declined While Zacks Investment Management Cut Its Position by $3.51 Million

July 17, 2017 - By Adrian Erickson

Investors sentiment increased to 1.1 in 2016 Q4. Its up 0.05, from 1.05 in 2016Q3. It increased, as 66 investors sold MRK shares while 603 reduced holdings. 128 funds opened positions while 609 raised stakes. 1.96 billion shares or 0.02% more from 1.96 billion shares in 2016Q3 were reported. 55,425 were accumulated by Alley Ltd Co. Td Asset Mgmt reported 2.57 million shares. Moreover, Vaughan David Invests Incorporated Il has 0.13% invested in Merck & Co., Inc. (NYSE:MRK). Schulhoff & Inc owns 10,665 shares for 0.39% of their portfolio. Amica Mutual Ins stated it has 0.8% in Merck & Co., Inc. (NYSE:MRK). Swedbank invested in 1.79% or 3.86 million shares. Cambridge Invest Rech Advisors holds 195,501 shares or 0.22% of its portfolio. Fincl Architects has 0.43% invested in Merck & Co., Inc. (NYSE:MRK). Beaumont Fin Ptnrs Ltd Liability Company reported 0.59% stake. The Massachusetts-based Eagleclaw Cap Managment Ltd Liability Corporation has invested 0.99% in Merck & Co., Inc. (NYSE:MRK). Psagot Inv House Limited has 0.09% invested in Merck & Co., Inc. (NYSE:MRK) for 34,916 shares. Guardian Capital Advsrs LP holds 4,527 shares. Alpha Windward Limited Liability Company stated it has 5,785 shares or 0.22% of all its holdings. Trustmark Comml Bank Trust Department invested 0.39% in Merck & Co., Inc. (NYSE:MRK). Northstar Gru holds 0.52% or 12,720 shares in its portfolio.

Zacks Investment Management decreased its stake in Merck & Co Inc (MRK) by 5.05% based on its latest 2016Q4 regulatory filing with the SEC. Zacks Investment Management sold 60,498 shares as the company’s stock declined 2.46% while stock markets rallied. The institutional investor held 1.14 million shares of the health care company at the end of 2016Q4, valued at $66.98 million, down from 1.20M at the end of the previous reported quarter. Zacks Investment Management who had been investing in Merck & Co Inc for a number of months, seems to be less bullish one the $172.95B market cap company. It closed at $63.06 lastly. It is down 16.86% since July 17, 2016 and is uptrending. It has outperformed by 0.16% the S&P500.

Zacks Investment Management, which manages about $3.45B and $3.48B US Long portfolio, upped its stake in Marsh & Mclennan Cos Inc (NYSE:MMC) by 51,444 shares to 697,514 shares, valued at $47.15 million in 2016Q4, according to the filing. It also increased its holding in Insight Enterprises Inc (NASDAQ:NSIT) by 108,328 shares in the quarter, for a total of 115,896 shares, and has risen its stake in Colgate Palmolive Co (NYSE:CL).

Investors wait Merck & Co., Inc. (NYSE:MRK) to report on July, 28. its quarterly earnings Wall Street analysts expect $0.88 earnings per share, down $0.05 or 5.38 % from last year’s $0.93 same quarter earnings. This translates into $2.41 billion profit for MRK giving the stock a 17.91 P/E. This is assuming the current $0.88 EPS is accurate. Merck & Co., Inc.’s Wall Street analysts see 0.00 % EPS growth, taking into account the $0.88 EPS reproted in the previous quarter,

More notable recent Merck & Co., Inc. (NYSE:MRK) news were published by: Seekingalpha.com which released: “Hold On, Merck’s CETP Inhibitor Actually Works?” on June 29, 2017, also Seekingalpha.com with their article: “Merck’s Constant Struggle With Leverage” published on July 13, 2017, Seekingalpha.com published: “The Merck Malware Attack” on June 29, 2017. More interesting news about Merck & Co., Inc. (NYSE:MRK) were released by: Fool.com and their article: “Better Buy: Eli Lilly and Co. vs. Merck & Co., Inc.” published on June 27, 2017 as well as Seekingalpha.com‘s news article titled: “Merck: Good Long-Term Despite Major Setback” with publication date: July 06, 2017.

Merck & Co., Inc. (NYSE:MRK) Ratings Coverage

Among 18 analysts covering Merck & Co. Inc. (NYSE:MRK), 13 have Buy rating, 2 Sell and 3 Hold. Therefore 72% are positive. Merck & Co. Inc. had 41 analyst reports since August 13, 2015 according to SRatingsIntel. The company was maintained on Thursday, August 27 by Jefferies. Jefferies maintained Merck & Co., Inc. (NYSE:MRK) rating on Thursday, May 25. Jefferies has “Sell” rating and $51 target. The stock of Merck & Co., Inc. (NYSE:MRK) has “Buy” rating given on Tuesday, November 24 by Berenberg. Jefferies maintained Merck & Co., Inc. (NYSE:MRK) rating on Thursday, July 14. Jefferies has “Hold” rating and $53 target. The firm has “Underperform” rating by Jefferies given on Monday, December 19. The firm has “Neutral” rating given on Wednesday, January 27 by Bank of America. The stock has “Sell” rating by BMO Capital Markets on Tuesday, July 4. The company was upgraded on Tuesday, December 1 by Barclays Capital. The firm has “Buy” rating by Bank of America given on Thursday, October 13. Argus Research maintained the shares of MRK in report on Tuesday, November 17 with “Buy” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.